Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | PARP10 | Q53GL7 | 13/20 | 0.47 |
| ▸ | PARP11 | Q9NR21 | 9/20 | 0.47 |
| ▸ | PARP1 | P09874 | 7/20 | 0.47 |
| ▸ | F7 | P08709 | 1/20 | 0.47 |
| ▸ | F3 | P13726 | 1/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10201433 | 0.90 | KDM4E (0.41) | KDM4EPARP10PARP11PARP1F7 | |
| SCHEMBL24136646 | 0.85 | KDM4E (0.56) | KDM4EPARP10PARP11PARP1F7 | |
| SCHEMBL29600821 | 0.85 | KDM4E (0.56) | KDM4EPARP10PARP11PARP1F7 | |
| SCHEMBL15830717 | 0.79 | PARP10 (0.56) | KDM4EPARP10PARP11PARP1F7 | |
| SCHEMBL31443844 | 0.79 | PARP10 (0.56) | KDM4EPARP10PARP11PARP1F7 | |
| SCHEMBL4500561 | 0.79 | PARP10 (0.56) | KDM4EPARP10PARP11PARP1F7 | |
| SCHEMBL29977721 | 0.76 | PARP10 (0.56) | KDM4EPARP10PARP11PARP1F7 | |
| SCHEMBL20488275 | 0.76 | PARP10 (0.56) | KDM4EPARP10PARP11PARP1F7 | |
| SCHEMBL31167714 | 0.76 | PARP10 (0.47) | KDM4EPARP10PARP11PARP1F7 | |
| SCHEMBL15831695 | 0.76 | PARP10 (0.47) | KDM4EPARP10PARP11PARP1F7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217966-A1 | PHARMACEUTICAL COMPOSITION CONTAINING GLP-1 RECEPTOR AGONIST HAVING FUSED RING | SHIONOGI & CO., LTD. (JP) | 2024-07-04 | — | — | US | disclosed |
| US-8569336-B2 | Compounds for the treatment of inflammatory disorders | TONG LING (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569336-B2 | Compounds for the treatment of inflammatory disorders | TONG LING (US) | 2013-10-29 | — | — | US | disclosed |
| US-20120015926-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TONG LING (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015926-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TONG LING (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217966-A1 | PHARMACEUTICAL COMPOSITION CONTAINING GLP-1 RECEPTOR AGONIST HAVING FUSED RING | GLP1R, GIPR, GCGR | KDM4E 3785/4885PARP10 2063/4885PARP11 2655/4885 |
| US-20120015926-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TNF, ADAMTS1, ADAMTS7 | KDM4E 4592/4885PARP10 2737/4885PARP11 2380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.